

Supplementary Table 1. Demographic and clinical characteristics of the main study cohort.

	SARS-CoV-2 Negative	SARS-CoV-2 Positive Mild (outpatients)	SARS-CoV-2 Positive Moderate (Inpatients)	SARS-CoV-2 Positive Severe (ICU)
Number (<i>n</i>)	20	20	20	20
Female, <i>n</i> (%)	10 (50)	12 (60)	11 (55)	7 (35)
Age, years, median (IQR)	55.5 (15.6)	52.5 (12.75)	58.5 (4.25)	58 (9.25)
Deceased, <i>n</i> (%)	0 (0)	0 (0)	2 (10)	6 (30)
Body mass index (BMI)				
Normal Weight (<25), %	-	6.7*	25	5
Overweight/obese (>25), %	-	93.3*	75	95
Pre-diabetes, %	-	6.7*	15	30
Diabetes Mellitus (DM), %	-	6.7*	30	55
High blood pressure, %	-	33.3*	60	60
Asthma, %	-	13.3*	15	5
Hydroxychloroquine, %	-	6.7*	40	55
Remdesivir, %	-	-	5	25
Tocilizumab, %	-	-	5	30
Chronic Steroid Use, %	-	-	25	5
Acute Steroid Use, %	-	-	15	45
Plasma IV nutrition, %	-	-	0	0
Enteral nutrition use, %	-	-	100	100
Antibiotic administration, %	-	-	60	85
Ethnicity	-	-		
African American, <i>n</i> (%)	0	0	9 (45)	7 (35)
Hispanic or Latino	0	2 (10.0)	6 (30)	9 (45)
Caucasian, <i>n</i> (%)	3 (15.0)	13 (65.0)	4 (20)	3 (15)
Other, <i>n</i> (%)	2 (10.0)	1 (5.0)	0	1 (5)
Unknown, <i>n</i> (%)	15 (75.0)	4 (20.0)	1 (5)	0

*Based on 15 out of 20 donors with available data